AmpliPhi Presents Case Study of Bacteriophage Used to Treat Drug Resistant Infection in Cystic Fibrosis Patient

AmpliPhi Biosciences Corporation (NYSE American: APHB) announced on 5/7/2018 a poster presentation of a successful case study of a patient with cystic fibrosis, suffering from recurrent multi-drug resistant (MDR)  Pseudomonas aeruginosa  (P. aeruginosa) pneumonia, who received treatment with AB-PA01, AmpliPhi’s investigational bacteriophage drug candidate.